In a historic move, the FDA has requested the removal of the black box warning from hormone therapy used for menopause. Experts say this long-overdue update reflects modern science—and could help women reclaim access to safe, effective symptom relief.
The FDA has approved Lynkuet (Elinzanetant), a groundbreaking non-hormonal medication that targets the brain pathways behind hot flashes. For women who can’t or prefer not to use hormone therapy, this represents a major step forward in menopause care.
A year-long study of Elinzanetant (Lynkuet) reveals lasting relief from hot flashes and improved sleep without hormones. Here’s what you need to know about this breakthrough non-hormonal option.
UK approves first testosterone cream for postmenopausal women—sparking hope for future FDA approval in the U.S.
Could a weekly pill shift the menopause timeline? Researchers are exploring how one drug might change the future of women’s health.